COMPARISON OF IPRONIAZID WITH OTHER AMINE OXIDASE INHIBITORS, INCLUDING W‐1544, JB‐516, RO 4–1018, and RO 5–0700

Bailey, Samuel d'A.; Bucci, L; Gosline, Ernest; Kline, Nathan S.; Park, Inho; Rochlin, D. G.; Saunders, John C.; Vaisberg, M. S.

doi:10.1111/j.1749-6632.1959.tb49243.x

Cited by 37 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contemporary with the discovery of the antimanic properties of lithium [22, 23] (now a standard first-line treatment for bipolar disorder) and the antipsychotic/antimanic properties of chlorpromazine [24, 25] (a treatment for schizophrenia), the first antidepressant medications were identified in the mid-1950’s. These included the tricyclic compound imipramine [26] and the monoamine oxidase inhibitor (MAOI) iproniazid [27, 28], leading to the “monoamine hypothesis” of depression [29–31]. Research in depression then largely shifted to delineating the neurochemical bases of the disorder and helped establish a role for serotonin, norepinephrine and dopamine dysfunction in the pathophysiology and treatment of depression.…”

Section: A Century Of Antidepressant Treatment Research: Limited Progmentioning

confidence: 99%

Stuck in a rut: rethinking depression and its treatment

Holtzheimer

Mayberg

2011

Trends in Neurosciences

367

222

View full text Add to dashboard Cite

The current definition of Major Depressive Disorder (MDD) emerged from efforts to create reliable diagnostic criteria for clinical and research use. However, despite decades of research, the neurobiology of MDD is largely unknown, and treatments are no more effective today than they were 50-70 years ago. We propose that the current conception of depression is misguiding basic and clinical research. Redefinition is necessary and may include a focus on a more narrowly defined set of core symptoms. However, we conclude that depression is better defined as the tendency to enter into, and inability to disengage from, a negative mood state rather than the mood state per sé. The implications for future clinical and basic research are discussed.

show abstract

Section: A Century Of Antidepressant Treatment Research: Limited Progmentioning

confidence: 99%

Stuck in a rut: rethinking depression and its treatment

Holtzheimer

Mayberg

2011

Trends in Neurosciences

367

222

View full text Add to dashboard Cite

show abstract

“…The mid-twentieth-century discovery of medications with antimanic (Cade 1949, Schou et al 1954), antipsychotic (Bower 1954, Winkelman 1954), and antidepressant effects (Bailey et al 1959, Kiloh et al 1960, Kuhn 1958) essentially ended the lobotomy era. However, using novel stereotactic neurosurgical techniques allowing more focal ablation (initially viewed as a potential substitute for prefrontal leucotomy in psychiatric patients) (Hariz et al 2010, Spiegel et al 1947), surgery for severe, intractable psychiatric disorders has continued in a limited fashion.…”

Section: Neurosurgery For Psychiatric Disordersmentioning

confidence: 99%

Deep Brain Stimulation for Psychiatric Disorders

Holtzheimer

Mayberg

2011

Annu. Rev. Neurosci.

257

161

View full text Add to dashboard Cite

Medications, psychotherapy, and other treatments are effective for many patients with psychiatric disorders. However, with currently available interventions, a substantial number of patients experience incomplete resolution of symptoms, and relapse rates are high. In the search for better treatments, increasing interest has focused on focal neuromodulation. This focus has been driven by improved neuroanatomical models of mood, thought, and behavior regulation, as well as by more advanced strategies for directly and focally altering neural activity. Deep brain stimulation (DBS) is one of the most invasive focal neuromodulation techniques available; data have supported its safety and efficacy in a number of movement disorders. Investigators have produced preliminary data on the safety and efficacy of DBS for several psychiatric disorders, as well. In this review, we describe the development and justification for testing DBS for various psychiatric disorders, carefully consider the available clinical data, and briefly discuss potential mechanisms of action.

show abstract